WallStreetZenWallStreetZen

NASDAQ: ALDX
Aldeyra Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALDX

Based on 2 analysts offering 12 month price targets for Aldeyra Therapeutics Inc

Min Forecast
$9.00+223.74%
Avg Forecast
$9.50+241.73%
Max Forecast
$10.00+259.71%

Should I buy or sell ALDX stock?

Based on 2 analysts offering ratings for Aldeyra Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALDX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ALDX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ALDX stock forecasts and price targets.

ALDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-19
lockedlocked$00.00+00.00%2025-04-07

1 of 1

Forecast return on equity

Is ALDX forecast to generate an efficient return?

Company
37.98%
Industry
140.91%
Market
90.47%
ALDX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALDX forecast to generate an efficient return on assets?

Company
25.92%
Industry
32.45%
ALDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALDX earnings per share forecast

What is ALDX's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.90
Avg 2 year Forecast
$0.19
Avg 3 year Forecast
-$0.25

ALDX revenue forecast

What is ALDX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$20.8M
Avg 2 year Forecast
$79.2M
Avg 3 year Forecast
$66.3M

ALDX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALDX$2.78$9.50+241.73%Strong Buy
PBYI$3.35$7.00+108.96%Buy
CYBN$8.35$86.00+929.94%Strong Buy
SLS$1.66N/AN/A
EDIT$1.97$4.00+103.05%Buy
View Top Biotech Stocks

Aldeyra Therapeutics Stock Forecast FAQ

Is Aldeyra Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ALDX) stock is to Strong Buy ALDX stock.

Out of 2 analysts, 1 (50%) are recommending ALDX as a Strong Buy, 1 (50%) are recommending ALDX as a Buy, 0 (0%) are recommending ALDX as a Hold, 0 (0%) are recommending ALDX as a Sell, and 0 (0%) are recommending ALDX as a Strong Sell.

If you're new to stock investing, here's how to buy Aldeyra Therapeutics stock.

What is ALDX's earnings growth forecast for 2025-2027?

(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Aldeyra Therapeutics's earnings in 2025 is -$57,698,823.On average, 3 Wall Street analysts forecast ALDX's earnings for 2025 to be -$53,906,029, with the lowest ALDX earnings forecast at -$78,463,220, and the highest ALDX earnings forecast at -$32,343,618. On average, 3 Wall Street analysts forecast ALDX's earnings for 2026 to be $11,380,162, with the lowest ALDX earnings forecast at -$64,088,279, and the highest ALDX earnings forecast at $113,801,617.

In 2027, ALDX is forecast to generate -$15,171,552 in earnings, with the lowest earnings forecast at -$40,130,044 and the highest earnings forecast at $15,572,853.

What is ALDX's revenue growth forecast for 2025-2027?

(NASDAQ: ALDX) Aldeyra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Aldeyra Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALDX's revenue for 2025 to be $1,248,224,054, with the lowest ALDX revenue forecast at $1,248,224,054, and the highest ALDX revenue forecast at $1,248,224,054. On average, 3 Wall Street analysts forecast ALDX's revenue for 2026 to be $4,744,509,212, with the lowest ALDX revenue forecast at $988,277,202, and the highest ALDX revenue forecast at $10,062,458,784.

In 2027, ALDX is forecast to generate $3,973,233,726 in revenue, with the lowest revenue forecast at $2,401,813,079 and the highest revenue forecast at $6,493,280,695.

What is ALDX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ALDX) forecast ROA is 25.92%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is ALDX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ALDX price target, the average ALDX price target is $9.50, with the highest ALDX stock price forecast at $10.00 and the lowest ALDX stock price forecast at $9.00.

On average, Wall Street analysts predict that Aldeyra Therapeutics's share price could reach $9.50 by May 19, 2026. The average Aldeyra Therapeutics stock price prediction forecasts a potential upside of 241.73% from the current ALDX share price of $2.78.

What is ALDX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ALDX) Aldeyra Therapeutics's current Earnings Per Share (EPS) is -$0.97. On average, analysts forecast that ALDX's EPS will be -$0.90 for 2025, with the lowest EPS forecast at -$1.31, and the highest EPS forecast at -$0.54. On average, analysts forecast that ALDX's EPS will be $0.19 for 2026, with the lowest EPS forecast at -$1.07, and the highest EPS forecast at $1.90. In 2027, ALDX's EPS is forecast to hit -$0.25 (min: -$0.67, max: $0.26).

What is ALDX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ALDX) forecast ROE is 37.98%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.